Drugs & Aging

, Volume 19, Issue 10, pp 793–805

Health-Related Quality of Life and Long-Term Therapy with Pravastatin and Tocopherol (Vitamin E) in Older Adults

  • Cynthia M. Carlsson
  • Kristi Papcke-Benson
  • Molly Carnes
  • Patrick E. McBride
  • James H. Stein
Original Research Article

DOI: 10.2165/00002512-200219100-00008

Cite this article as:
Carlsson, C.M., Papcke-Benson, K., Carnes, M. et al. Drugs Aging (2002) 19: 793. doi:10.2165/00002512-200219100-00008

Abstract

Introduction: Concerns about the effects of HMG-CoA reductase inhibitors (‘statins’) on health-related quality of life may contribute to their underuse in older adults with and at risk for cardiovascular disease. These concerns also may prevent clinicians from enrolling older patients in clinical trials assessing the efficacy of statins as a preventive therapy for Alzheimer’s disease.

Objective: To determine the effects of pravastatin and tocopherol (vitamin E), alone and in combination, on health-related quality of life in older adults.

Study design: Double-blind, randomised, placebo-controlled, crossover study.

Participants: Forty-one community-dwelling men and women aged ≥70 years with low-density lipoprotein-cholesterol (LDL-C) ≥3.62 mmol/L (140 mg/dl) participated.

Methods: Subjects received pravastatin for 6 months then pravastatin plus tocopherol for an additional 6 months (group 1), or tocopherol for 6 months then pravastatin plus tocopherol for an additional 6 months (group 2). Dosages were pravastatin 20mg daily and tocopherol 400IU daily.

Main outcome measures: The following health-related quality-of-life measures were assessed at baseline, after 6 months and after 1 year: health perception, depression, physical function, cognitive function and sleep behaviour. In addition, data on adverse effects and laboratory abnormalities were obtained.

Results: Pravastatin reduced levels of total cholesterol (−21%, p < 0.001) and LDL-C (−29%, p < 0.001). Health-related quality-of-life scores, physical adverse effects, muscle enzyme levels and liver function tests did not change after 12 months of therapy with pravastatin, tocopherol or their combination.

Conclusion: Both pravastatin and tocopherol have a good safety profile, are well tolerated and do not adversely affect health-related quality of life in older patients with hypercholesterolaemia. Given the significant beneficial cardiovascular effects of statin therapy in older adults and the potential role of statins in prevention of Alzheimer’s disease, concerns about adverse effects on quality of life should not deter use of these medications in this population.

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Cynthia M. Carlsson
    • 1
  • Kristi Papcke-Benson
    • 1
  • Molly Carnes
    • 1
  • Patrick E. McBride
    • 1
  • James H. Stein
    • 1
  1. 1.Section of Cardiovascular MedicineUniversity of Wisconsin Medical School, H6/315 Clinical Science Center (3248)MadisonUSA

Personalised recommendations